2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.

January 28 | 2021

2cureX is pleased to announce that Kenneth Graabek Johansen has been appointed new CFO and will start on 1 February 2021. Kenneth has a strong track record in business administration at executive level in the biomedical area.

Early January 2021 2cureX has appointed Fernando Andreu as CEO (see link to pressrelease) to lead the transition of 2cureX from being a Research & Development company to become a full-fleshed commercial company with products on the market.

Today, 2cureX is pleased to announce, that Kenneth Graabek Johansen also will be joining the company as CFO. With positions such as COO and Co-founder of JADBio, a developer of Artificial Intelligence and Machine Learning solutions applied to Life Sciences, Kenneth will add many years of experience in strengthening the business and financial development dimension, which is key to positioning 2cureX as a world leader in Functional Precision Medicine.

Significant strengthening of the Executive Leadership Team

Ole Thastrup, CEO and Founder (CSO and deputy-CEO from 1 February 2021): “I am very pleased to welcome Kenneth Graabek Johansen as our new CFO adding extensive international biomedical experience to the company. In addition, I am happy to announce, that our newly appointed CEO, Fernando Andreu will start on the same day as Kenneth – 1. February. Fernando and Kenneth have worked together in the past and they will undoubtedly give the roll-out of IndiTreat a flying start in Europe. We are entering an incredibly exciting phase of the 2cureX commercialization journey”.

Fernando Andreu, nominated CEO (CEO from 1. February): "I am delighted to have Kenneth joining 2cureX as CFO. Kenneth and I had the chance to work together in the past, and he brings in a rare combination of strong financial expertise and entrepreneurial mindset. Our immediate priorities are the geographic expansion of Inditreat and the scale up of our internal operations, and in this situation a profile like Kenneth's will be a fantastic addition to the management team. His experience in the AI / ML environment will also be very relevant for our mid-term plans".

Kenneth Graabek Johansen, (CFO from 1. February 2021): “I am really looking forward to join such a strong team at 2cureX. The knowledge base and cutting-edge technology that 2cureX is bringing to market with IndiTreat is an important part of the efforts to advance individualized patient treatment, and I am honored to contribute to supporting and accelerating of these efforts. In addition to ensuring robust financial management, I am looking forward to utilizing my experience with scaling business and further advancing on the AI and ML opportunities”.

For further information, please contact:

Ole Thastrup, CEO
Phone: +45 22 11 53 99
Mail: ot@2curex.com

Certified Adviser

Redeye AB
Phone: +46 8 121 576 90
Mail: certifiedadviser@redeye.se

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 28th, 2021.

About Kenneth Graabek Johansen’s experience
Kenneth is bringing more that 15 years of experience in business development and financial administration from intersection of the biomedical area and advanced data analysis. His experience spans from COO of JADBio (Greece), CEO of Raven biosciences (DK), CEO of QIAGEN Aarhus (DK) and CFO of CLC bio (DK). In addition to this he also held management positions such as CFO with Timextender (DK) and CAO with SHL (DK), and several years working in audit with KPMG (DK). Please visit Kenneth’s LinkedIn profile to learn more.

About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is presently being introduced into the European market. The aspiration is that IndiTreat® becomes a standard Functional Precision Medicine tool for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX please visit www.2cureX.com